JP2015509938A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509938A5
JP2015509938A5 JP2014557760A JP2014557760A JP2015509938A5 JP 2015509938 A5 JP2015509938 A5 JP 2015509938A5 JP 2014557760 A JP2014557760 A JP 2014557760A JP 2014557760 A JP2014557760 A JP 2014557760A JP 2015509938 A5 JP2015509938 A5 JP 2015509938A5
Authority
JP
Japan
Prior art keywords
seq
antibody
chain variable
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014557760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509938A (ja
JP6273214B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/026087 external-priority patent/WO2013123152A2/en
Publication of JP2015509938A publication Critical patent/JP2015509938A/ja
Publication of JP2015509938A5 publication Critical patent/JP2015509938A5/ja
Application granted granted Critical
Publication of JP6273214B2 publication Critical patent/JP6273214B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014557760A 2012-02-17 2013-02-14 がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用 Expired - Fee Related JP6273214B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US61/600,499 2012-02-17
US201261602511P 2012-02-23 2012-02-23
US61/602,511 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (3)

Publication Number Publication Date
JP2015509938A JP2015509938A (ja) 2015-04-02
JP2015509938A5 true JP2015509938A5 (https=) 2016-01-28
JP6273214B2 JP6273214B2 (ja) 2018-01-31

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557760A Expired - Fee Related JP6273214B2 (ja) 2012-02-17 2013-02-14 がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用

Country Status (13)

Country Link
US (5) US9493566B2 (https=)
EP (1) EP2814509B1 (https=)
JP (1) JP6273214B2 (https=)
KR (1) KR102084806B1 (https=)
CN (2) CN104220094A (https=)
AU (1) AU2013221585B2 (https=)
BR (1) BR112014019861A2 (https=)
CA (1) CA2862319C (https=)
EA (1) EA031069B1 (https=)
IL (1) IL233742B (https=)
MX (1) MX360141B (https=)
SG (1) SG11201404354UA (https=)
WO (1) WO2013123152A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
CA2925057A1 (en) * 2013-10-01 2015-04-09 Simon T. BARRY Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CA2937753A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
US20170233452A1 (en) * 2014-04-23 2017-08-17 Immusoft Corporation Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
TWI851531B (zh) 2016-08-09 2024-08-11 美商思進公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
CA3039589A1 (en) 2016-10-18 2018-04-26 Seattle Genetics, Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
SI3535397T1 (sl) 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
CA3059803A1 (en) * 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CA3060206A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
WO2019089765A1 (en) * 2017-11-01 2019-05-09 Arrowhead Pharmcaceuticals, Inc. Integrin ligands and uses thereof
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
SG11202007540SA (en) 2018-02-20 2020-09-29 Seattle Genetics Inc Hydrophobic auristatin f compounds and conjugates thereof
US20240199735A1 (en) * 2019-07-22 2024-06-20 The Methodist Hospital Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
US11827709B2 (en) * 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
JP2024516096A (ja) 2021-04-08 2024-04-12 アローヘッド ファーマシューティカルズ インコーポレイテッド 終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法
CN117597150A (zh) 2021-04-20 2024-02-23 思进公司 抗体依赖性细胞毒性的调节
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer
EP4731670A2 (en) 2023-06-23 2026-04-29 Mythic Therapeutics, Inc. Ph sensitive anti-itgb6 antibodies and uses thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
ATE511850T1 (de) 1997-08-08 2011-06-15 Univ California Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin
EP2165714B1 (en) 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
UA90242C2 (ru) * 2002-03-13 2010-04-26 Байоджен Айдек Ма Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С αVβ6
NZ535425A (en) * 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
CA2481922A1 (en) 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US7241598B2 (en) 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
AU2005294131A1 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
US8603483B2 (en) * 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
AU2006286498A1 (en) 2005-08-31 2007-03-08 Novo Nordisk Health Care Ag Human FVII monoclonal antibodies binding the GLA domain and use thereof
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
EP2064244B1 (en) 2006-08-03 2019-06-05 MedImmune Limited ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
JP2010506944A (ja) 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
EP2241578B1 (en) * 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
JP2011509687A (ja) * 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｒｏｎ抗体およびその使用
JP5467997B2 (ja) 2008-03-27 2014-04-09 テルモ株式会社 生体吸収性材料およびそれを用いた生体内留置物
CA2723842A1 (en) 2008-05-09 2009-11-12 Peter Vanlandschoot Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
KR101138460B1 (ko) * 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
HK1208470A1 (en) 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications

Similar Documents

Publication Publication Date Title
JP2015509938A5 (https=)
JP2023509196A5 (https=)
JP2022093564A5 (https=)
JP2016536020A5 (https=)
CN115052893A (zh) 抗tigit抗体和使用方法
JP2014531201A5 (https=)
JP2020501531A5 (https=)
JP2017500028A5 (https=)
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
JP2014511179A5 (https=)
JP2013529059A5 (https=)
JP2014509835A5 (https=)
JP2019513701A5 (https=)
JP2017519759A5 (https=)
JP2015504421A5 (https=)
JP2014522850A5 (https=)
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
JP2017514461A5 (https=)
NZ714482A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP2014506120A5 (https=)
JP2013544492A5 (https=)
RU2016137110A (ru) Антитела к компоненту комплемента с5
HRP20240415T1 (hr) Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba
JP2018507188A5 (https=)
RU2016118573A (ru) Анти-ly6e антитела и способы применения